Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer

Table 3 ROC curve results based on FAR, FPR, NLR, PLR, LMR, PNI, FLR, and CA199 for distinguish PC patients from OPT in testing set 1

Marker	AUC (95%CI)	P—value	cut-off	Sensitivity	Specificity
FAR	0.778(0.740–0.817)	< 0.0001	0.070	0.701	0.734
FPR	0.779(0.740–0.817)	< 0.0001	0.013	0.778	0.666
NLR	0.716(0.674–0.759)	< 0.0001	1.961	0.674	0.642
PLR	0.648(0.603–0.694)	< 0.0001	128.575	0.679	0.565
MLR	0.697(0.654–0.741)	< 0.0001	0.271	0.733	0.607
PNI	0.714(0.671–0.757)	< 0.0001	47.225	0.774	0.595
FLR	0.813(0.778–0.848)	< 0.0001	1.631	0.747	0.743
CA199	0.846(0.812–0.880)	< 0.0001	32.205	0.887	0.772
CA199 + FAR	0.914(0.891–0.937)	< 0.0001	-0.182	0.896	0.799
CA199 + FPR	0.915(0.891–0.938)	< 0.0001	0.101	0.860	0.831
CA199 + FLR	0.915(0.829–0.938)	< 0.0001	-0.523	0.946	0.778
CA199 + FAR + FPR	0.917(0.895–0.940)	< 0.0001	-0.125	0.887	0.799
CA199 + FAR + FPR + FLR	0.924(0.903–0.946)	< 0.0001	-0.506	0.941	0.799

Abbreviations: PC Pancreatic cancer, OPT Other pancreas tumors, ROC Receiver operating characteristic, AUC Area under the receiver operating characteristic curve, CI Confidence interval, FPR Fibrinogen-to-prealbumin ratio, FAR Fibrinogen-to-albumin ratio, NLR Neutrophil-to-lymphocyte ratio, PLR Platelets-to-lymphocyte ratio, MLR Monocytes-to-lymphocyte ratio, PNI Albumin + 5 × the lymphocyte count, FLR Fibrinogen-to- lymphocyte ratio

ISSN: 1471-2407